News

Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Tarceva (erlotinib) tablets, 100 and 150 mg, in the U.S. Erlotinib Tablets are a kinase inhibitor…
Read More...

Adimab announced the expansion of an earlier multi-target research agreement with Regeneron Pharmaceuticals. Adimab and Regeneron commenced an initial agreement in December 2014,…
Read More...

Bayer announced it will invest $150 million in its Berkeley, CA pharmaceutical development and manufacturing site to build a Cell Culture Technology Center that will be used to…
Read More...

Pfizer Inc. announced the opening of a new 175,000 square-foot manufacturing facility in Andover, Mass. Pfizer’s Andover site houses commercial manufacturing and product development…
Read More...

Armata Pharmaceuticals announced that the previously-announced merger between C3J Therapeutics, Inc. and AmpliPhi Biosciences Corporation has closed. The new combined company, known as…
Read More...

WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring and neuromodulation, has enrolled its first patient in the pivotal clinical study of…
Read More...

Sartorius Stedim Biotech (SSB) announced the new SIMCA 16 software for multivariate data analytics is available from its subsidiary Sartorius Stedim Data Analytics. The updated SIMCA…
Read More...

Pfizer announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare…
Read More...

Akcea Therapeutics and Ionis Pharmaceuticals announced that WAYLIVRA has received conditional marketing authorization from the European Commission (EC) as an adjunct to diet in adult…
Read More...

Novartis announced results from a validation study of the innovative, algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscuss. The tool aims to support and…
Read More...

Merck, known as MSD outside the United States and Canada, announced the presentation of results of a Phase 3 trial evaluating the efficacy and safety of BELSOMRA (suvorexant) C-IV for…
Read More...

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, announced a collaboration with…
Read More...

Verve Therapeutics announced its launch to discover and develop therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, the…
Read More...

The European Commission has approved Dupixent (dupilumab) for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2…
Read More...

Pfizer Inc. announced that the European Commission (EC) granted conditional marketing authorization for LORVIQUA (lorlatinib, available in the U.S., Canada and Japan under the brand…
Read More...

Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced a clinical trial collaboration with AstraZeneca to…
Read More...

Ligand Pharmaceuticals Incorporated announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections,…
Read More...

Xencor announced that the first patient has been dosed in XmAb23104-01 (DUET-3), a Phase 1 clinical study to evaluate the safety and tolerability of XmAb23104, a bispecific antibody…
Read More...

On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused…
Read More...

Skyhawk Therapeutics announced a strategic collaboration with Takeda Pharmaceutical Company Limited (Takeda) in which Skyhawk will use its SkySTAR technology platform to discover and…
Read More...